Cholesterol medication effects on body weight
Pro Research Analysisby 
Searched over 200M research papers
Cholesterol Medications and Body Weight: Key Effects
Weight-Loss Medications and Cholesterol Profile
Several cholesterol-lowering and weight-loss medications have been studied for their effects on both body weight and lipid profiles. Orlistat, a lipase inhibitor, consistently reduces body weight by about 2 kg and also lowers total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, though the changes in cholesterol are modest. The reduction in cholesterol is more pronounced in patients who lose more weight and during shorter treatment durations 16. Other FDA-approved weight-loss medications, such as phentermine-topiramate and liraglutide, also show modest improvements in weight and some cardiometabolic risk factors, but their effects on cholesterol are generally small and vary by drug .
Metformin: Weight and Lipid Effects
Metformin, commonly used for type 2 diabetes, is generally considered weight-neutral, but studies in elderly and morbidly obese populations show it can lead to a small but significant reduction in body weight (about 2 kg) and slight improvements in total and LDL cholesterol levels 47. In nondiabetic, morbidly obese individuals, metformin also reduces waist circumference, insulin, and leptin levels, all of which are beneficial for cardiovascular health .
SGLT2 Inhibitors and Body Weight
SGLT2 inhibitors, such as dapagliflozin, are known to reduce body weight (about 3 kg) mainly through loss of body water and lean mass. However, despite these weight reductions and improved glucose control, they do not significantly affect HDL cholesterol levels or HDL functionality .
Tirzepatide: Weight Loss and Lipid Changes
Tirzepatide, a newer medication for obesity and type 2 diabetes, shows that changes in lipid profiles (total cholesterol, HDL, LDL, and triglycerides) can occur both with and without associated weight loss. In the first 24 weeks of treatment, most lipid changes are not directly linked to weight loss, but after 72 weeks, the majority of lipid improvements are associated with the amount of weight lost, especially for LDL cholesterol .
LDL Cholesterol-Lowering Drugs and Weight Gain
Some LDL cholesterol-lowering drugs may modestly increase body weight, and this weight gain can partially mediate the increased risk of developing type 2 diabetes seen with these medications. About 8–38% of the increased diabetes risk from lowering LDL cholesterol is explained by the associated increase in BMI .
Rimonabant: Weight and Lipid Effects
Rimonabant, a CB1 receptor blocker (no longer widely used due to side effects), was shown to significantly reduce body weight and waist circumference, increase HDL cholesterol, and lower triglycerides in overweight or obese patients with dyslipidemia .
Conclusion
Cholesterol medications can have varying effects on body weight, depending on the drug class. Some, like orlistat, metformin, and tirzepatide, can lead to modest weight loss and slight improvements in cholesterol profiles, while others, such as certain LDL-lowering drugs, may slightly increase body weight and diabetes risk. The relationship between weight change and cholesterol improvement is complex and often drug-specific, with some lipid changes occurring independently of weight loss. Overall, the impact of cholesterol medications on body weight is generally modest, but these changes can contribute to improved metabolic health in certain populations 1234+4 MORE.
Sources and full results
Most relevant research papers on this topic